A summary of industry trends from July 11, 2025, noting the Humira patent expiration, Johnson & Johnson's consistency, and Medtronic's dividend increases.
2 reports, 2 independent
Updated Fri 00:00
No new developments lately
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A summary of industry trends from July 11, 2025, noting the Humira patent expiration, Johnson & Johnson's consistency, and Medtronic's dividend increases.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
AbbVie
pharmaceutical company
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
Medtronic plc
medical device company
Related events
- Lost patent protection for Humira in the US on August 20, 2025.
- Pfizer, Johnson & Johnson, and Merck are facing significant industry pressures due to patent cliffs and market pricing demands.
- Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.
- AbbVie, Abbott Laboratories, and Johnson & Johnson were recommended as dividend stocks for retirees, operating in the healthcare sector.
- Biosimilar erosion is impacting market share, and AbbVie, Procter & Gamble, and Johnson & Johnson are noted as major consumer goods players.
Coverage
Newest first; wire copies grouped- aol.com
- Motley FoolWhat Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill Medtronic is approaching five decades of dividend growth. AbbVie rose to the challenge when its Humira patent expired,